Dimensional Fund Advisors LP acquired a new position in shares of MEI Pharma Inc (NASDAQ:MEIP) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 149,950 shares of the company’s stock, valued at approximately $402,000. Dimensional Fund Advisors LP owned 0.41% of MEI Pharma at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its stake in MEI Pharma by 2,508.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 67,825 shares of the company’s stock valued at $162,000 after purchasing an additional 65,225 shares during the period. Vanguard Group Inc. boosted its holdings in MEI Pharma by 12.3% in the second quarter. Vanguard Group Inc. now owns 740,580 shares of the company’s stock worth $1,770,000 after purchasing an additional 81,308 shares in the last quarter. OxFORD Asset Management LLP boosted its holdings in MEI Pharma by 116.2% in the second quarter. OxFORD Asset Management LLP now owns 235,025 shares of the company’s stock worth $562,000 after purchasing an additional 126,303 shares in the last quarter. Nationwide Fund Advisors bought a new stake in MEI Pharma in the third quarter worth $229,000. Finally, Russell Investments Group Ltd. boosted its holdings in MEI Pharma by 659.3% in the third quarter. Russell Investments Group Ltd. now owns 204,199 shares of the company’s stock worth $547,000 after purchasing an additional 177,306 shares in the last quarter. 21.51% of the stock is currently owned by hedge funds and other institutional investors.
MEIP has been the subject of a number of research analyst reports. Oppenheimer set a $7.00 target price on shares of MEI Pharma and gave the stock a “buy” rating in a research report on Monday, January 8th. Cann reissued a “buy” rating and issued a $6.50 price target on shares of MEI Pharma in a research report on Thursday, December 21st. Zacks Investment Research raised shares of MEI Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, February 10th. Finally, ValuEngine raised shares of MEI Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, February 7th.
MEI Pharma Inc (MEIP) traded up $0.04 on Monday, hitting $2.19. 51,900 shares of the stock traded hands, compared to its average volume of 121,194. MEI Pharma Inc has a twelve month low of $1.48 and a twelve month high of $3.26.
COPYRIGHT VIOLATION NOTICE: “Dimensional Fund Advisors LP Takes $402,000 Position in MEI Pharma Inc (NASDAQ:MEIP)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/19/dimensional-fund-advisors-lp-invests-402000-in-mei-pharma-inc-meip-stock.html.
About MEI Pharma
MEI Pharma, Inc is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.